# A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies

> **NCT07173595** · PHASE1 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 186 (estimated)

## Conditions studied

- Relapsed or Refractory Hematologic Malignancies

## Interventions

- **DRUG:** QLS2309

## Key facts

- **NCT ID:** NCT07173595
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-05
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07173595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07173595, "A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07173595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*